Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Regeneron announces FDA issues CRL for aflibercept 8 mg (Eylea HD) sBLA

The affected mandate requires that all newborns receive erythromycin ointment applied to their eyes after birth, which helps prevent ophthalmia neonatorum.

Prevent Blindness urges West Virginia State Legislature to reject bill removing newborn eye infection protection

Schwartz is an ophthalmologist and retina specialist at Moorfields Eye Hospital in London, England. Schwartz serves as medical adviser for Apellis Pharmaceuticals.

Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of 

for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of 

Ophthalmology Times, Ophthalmology Times Europe, Modern Retina 

 Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.

Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s 

Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.

In addition, she has served as a judge for 

 Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.

Insights from a genome-wide association study identify novel genetic loci

Unveiling genetic distinctions between reticular pseudodrusen and drusen

CsA Ophthalmic Gel is an innovative cyclosporine gel being developed by Zhaoke in China for the treatment of moderate to severe DED.

Zhaoke enrolls first patient in phase 3 trial of cyclosporine ophthalmic gel for dry eye

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

ASCRS

, discusses corneal cross-linking (CXL) complications, and when to consider CXL treatment at the 2019 annual 

Intense pulsed light therapy for the treatment of chalazia

Audrey Talley Rostov, MD, discusses corneal cross-linking (CXL) complications, and when to consider CXL treatment 

When to consider corneal cross-linking treatment

When to consider corneal cross-linking treatment

Newsletter